Transcriptomics

Dataset Information

2

Gene expression associated with lentiviral expression of PRAME in normal hematopoietic progenitors.


ABSTRACT: To identify gene expression that distinguishes hematopoietic cells that express PRAME from those that do not, normal CD34+ cells with forced PRAME expression were compared to cells without PRAME expression in culture over time (days 4, 7, 14) using Affymetrix HU-133A microarrays Normal CD34+ progenitor cells not expressing PRAME were transduced with either PRAME cDNA (no 3' utr) or a corresponding empty vector control by lentiviral vector infection. Two replicates were performed for each condition (PRAME and control) at three experimental time points (days 4, 7, and 14 in culture). A single-stranded linear amplification protocol was used to process total RNA (one microgram) for the microarrays. This protocols is described in detail in PMID 14706461.

ORGANISM(S): Homo sapiens  

SUBMITTER: Janis L Abkowitz   Katherine A Guthrie  Vivian G. Oehler  Ted Gooley  Mirjam T Epping  Jerald P Radich  Carrie L Cummings  Vivian G Oehler  Derek L Stirewalt  Taimei Yang  Brent L Wood  Paula Ladne  Era Pogosova-Agadjanyan  Kathleen Sabo  Yaping Shou 

PROVIDER: E-GEOD-17100 | ArrayExpress | 2009-10-31

SECONDARY ACCESSION(S): GSE17100PRJNA117821

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications

The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.

Oehler Vivian G VG   Guthrie Katherine A KA   Cummings Carrie L CL   Sabo Kathleen K   Wood Brent L BL   Gooley Ted T   Yang Taimei T   Epping Mirjam T MT   Shou Yaping Y   Pogosova-Agadjanyan Era E   Ladne Paula P   Stirewalt Derek L DL   Abkowitz Janis L JL   Radich Jerald P JP  

Blood 20090722 15


The preferentially expressed antigen in melanoma (PRAME) is expressed in several hematologic malignancies, but either is not expressed or is expressed at only low levels in normal hematopoietic cells, making it a target for cancer therapy. PRAME is a tumor-associated antigen and has been described as a corepressor of retinoic acid signaling in solid tumor cells, but its function in hematopoietic cells is unknown. PRAME mRNA expression increased with chronic myeloid leukemia (CML) disease progres  ...[more]

Similar Datasets

2016-02-23 | E-GEOD-78164 | ArrayExpress
2013-06-13 | E-GEOD-38767 | ArrayExpress
2014-09-08 | E-GEOD-55038 | ArrayExpress
2016-07-04 | E-GEOD-81329 | ArrayExpress
2012-11-17 | E-MTAB-1370 | ArrayExpress
2015-09-11 | E-GEOD-72867 | ArrayExpress
2012-11-02 | E-MEXP-3648 | ArrayExpress
2015-01-01 | E-GEOD-62734 | ArrayExpress
2014-09-08 | E-GEOD-54500 | ArrayExpress
2016-01-12 | E-GEOD-76746 | ArrayExpress